Mounjaro 7.6 mg: why this dose doesn't exist and what does

The myth: '7.6 mg' is a dose your prescriber skipped

One of the questions our prescribers hear most weeks is some version of: "I've seen 7.6 mg mentioned online, is that a stronger version, a different brand, or something my pharmacy should have?" The short answer is no. The figure appears to circulate on forums and occasionally in auto-suggested search terms, but it has no basis in the licensed product. Mounjaro's UK strengths were fixed at approval: 2.5, 5, 7.5, 10, 12.5 and 15 mg. There is no 7.6 mg pen, no 7.6 mg formulation and no clinical pathway that passes through it.

Why does the confusion matter? Because people searching for an unlicensed strength are sometimes being pointed toward unverified sellers. The MHRA has warned publicly that counterfeit tirzepatide pens have entered circulation in the UK, and a search for a dose that doesn't officially exist is a red flag worth taking seriously. If you've seen "7.6 mg" offered for sale anywhere, treat it with real caution and report the listing at the MHRA's Yellow Card portal, which handles suspect seller reports alongside adverse event reports.

The information on this page is drawn from the tirzepatide licence, and if you're interested in higher-strength formats you can find full details on our tirzepatide pre-filled pen 30 mg page. For the full prescribing detail, the NHS tirzepatide medicines page is the most accessible UK-verified source.

What 7.5 mg actually means in the titration schedule

Assuming the "7.6 mg" search is really a question about the 7.5 mg pen, here's the substance. Mounjaro's titration structure exists to give your body time to adjust to a dual GIP and GLP-1 receptor agonist, the mechanism that slows gastric emptying, increases satiety signals and influences blood-sugar regulation. Starting too high produces avoidable nausea; the stepwise approach keeps most people comfortable while appetite suppression builds.

The typical path runs: 2.5 mg for the first four weeks, then 5 mg for four weeks, then 7.5 mg. By the time someone reaches 7.5 mg they've usually been on treatment for around eight weeks and the initial GI adjustment period (the nausea, the early fullness, the occasional dizziness) has often settled. You can read more about the transition from the earlier dose on our 5 mg pen page. Our Mounjaro 7.5 mg page goes into detail on how the appetite effect typically deepens at this step, with weight loss that felt modest in the first two months often becoming more noticeable here.

The prescriber sets the pace. If 5 mg was poorly tolerated, staying at that level longer is clinically reasonable. If 7.5 mg produces significant GI side effects, the same logic applies. The schedule is a framework, not a timetable to push through.

Side effects to know at the 7.5 mg stage

The side-effect profile at 7.5 mg is broadly similar to earlier doses, but dose increases can temporarily intensify GI symptoms. Nausea is the most commonly reported; loose stools, indigestion, reflux and reduced appetite (which is also the intended effect) sit alongside it. These are usually most pronounced in the first week or two after moving up a step and tend to ease as the body adapts.

Injection-site reactions (mild redness or itching at the abdomen, thigh or upper arm) can occur at any dose. Rotating sites each week reduces this. The pen goes into subcutaneous fat, not muscle; the angle and technique matter, and the Patient Information Leaflet that comes with your pen covers this in detail.

More serious symptoms need prompt attention regardless of dose: severe abdominal pain that travels to the back (seek same-day medical advice, this can indicate pancreatitis), signs of an allergic reaction, or significant dehydration from prolonged vomiting or diarrhoea. If you have concerns about a symptom at any dose, our aftercare team is available seven days a week. For the full UK-verified side-effect list, the NHS tirzepatide page sets out what to watch for at every stage.

Eligibility, cost context and the private route at this dose

Mounjaro is licensed for adults with a BMI of 30 or above, or 27 and above alongside a weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnoea. The prescriber considers the whole clinical picture; BMI alone doesn't decide the outcome. You can explore the full dose range, including what our 4 mg Mounjaro page covers for those earlier in the titration journey, to understand where 7.5 mg sits in context.

On the NHS, access to tirzepatide is currently phased and governed by strict criteria, most people reaching 7.5 mg privately are doing so because they don't yet qualify for NHS treatment or because waiting lists mean private care is the practical option. For the cost picture across the treatment journey, our UK pricing context page explains the background to how Mounjaro's list price has changed and what a legitimate private prescription typically includes. The short version: at nume, one price covers the clinical consultation, the prescription, the medication and tracked next-working-day delivery, no separate charges, no subscription.

If you're considering starting treatment or moving to 7.5 mg through a private service, check your eligibility with our prescribers, consultations are free, and every order is reviewed by a real clinician before anything is dispatched.